The first study drug combination is modified FOLFOX6 (folic acid, leucovorin, fluorouracil, and oxaliplatin) mFOLFOX6 and bevacizumab. The second study drug combination is liposomal doxorubicin, bevacizumab, and temsirolimus. Patients in both combinations will also receive treatment with the NovoTTF-100L system.